Beta-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line use of Canakinumab An open-label canakinumab (ACZ885) dose reduction or dose interval prolongation efficacy and safety study in patients with Systemic Juvenile Idiopathic Arthritis (SJIA)
Phase of Trial: Phase III/IV
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Canakinumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms Beta-SPECIFIC-4-Patients
- Sponsors Novartis
- 15 Feb 2018 Status changed from recruiting to completed.
- 01 Nov 2017 This study has been completed in Germany on 25 Sep 2017 according to European clinical trials database record.
- 28 Oct 2017 This study has been completed in Sweden (end date: 25 Sep 2017).